Adios Max Tablets
Active ingredient: dry extract fucus
- 1. Name of the medicinal product
- 2. Qualitative and quantitative composition
- 3. Pharmaceutical form
- 4. Clinical particulars
- 4.1 Therapeutic indications
- 4.2 Posology and method of administration
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.6 Fertility, pregnancy and lactation
- 4.7 Effects on ability to drive and use machines
- 4.8 Undesirable effects
- 4.9 Overdose
- 5. Pharmacological properties
- 5.1 Pharmacodynamic properties
- 5.2 Pharmacokinetic properties
- 5.3 Preclinical safety data
- 6. Pharmaceutical particulars
- 6.1 List of excipients
- 6.2 Incompatibilities
- 6.3 Shelf life
- 6.4 Special precautions for storage
- 6.5 Nature and contents of container
- 6.6 Special precautions for disposal and other handling
- 7. Marketing authorisation holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text
1. Name of the medicinal product
Adios Max
2. Qualitative and quantitative composition
Each tablet contains:
120 mg of extract (as dry extract) from kelp thallus (Fucus vesiculosus L. or F. Serratus L. or Ascophyllum nodosum Le Jolis) (5:1).
Extraction solvent: water
For full list of excipients, see section 6.1.
Excipients with known effect
Each tablet contains 70 mg lactose and 130 mg sucrose and 180 micrograms of iodine (See section 4.4. 'Special warnings and precautions for use.')
3. Pharmaceutical form
Coated Tablet
White, circular, biconvex sugar-coated tablets.
4. Clinical particulars
4.1 Therapeutic indications
A traditional herbal medicinal product used as an aid to slimming as part of a calorie controlled diet, based on traditional use only.
4.2 Posology and method of administration
For oral use only.
Adults (18 years and above): One tablet three times a day.
This product should be taken as part of a calorie-controlled diet and extra exercise.
If symptoms do not improve or worsen during the use of this medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
The use in children and adolescents under 18 years and the elderly is not recommended (see Section 4.4. Special warnings and precautions for use).
4.3 Contraindications
Hypersensitivity to the active substances or to iodine or to any of the excipients.
Patients with a thyroid disorder.
4.4 Special warnings and precautions for use
Do not exceed the stated dose.
The use in children and adolescents under 18 years and the elderly is not recommended because data are insufficient and medical advice should be sought.
Do not take with other medicines or dietary supplements containing iodine.
Contains lactose and sucrose, patients with rare hereditary problems of galactose or fructose intolerance, glucose-galactose malabsorption, total lactase deficiency or sucrase-isomaltase insufficiency should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
No studies have been carried out to determine if drug interactions occur with this product.
Do not take with other medicines or dietary supplements containing iodine.
Do not take with medicines for thyroid disorders.
This product can theoretically have an effect on anticoagulant treatments. Patients taking anticoagulant treatments should not use the product.
4.6 Fertility, pregnancy and lactation
Safety during pregnancy and lactation has not been established.
In the absence of sufficient data the use in pregnancy and lactation is not recommended.
Studies on the effects on fertility have not been performed.
4.7 Effects on ability to drive and use machines
No studies on the effects of this product on the ability to drive or operate machinery have been performed.
4.8 Undesirable effects
May cause diarrhoea. The frequency is unknown.
If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
4.9 Overdose
An overdose may lead to thyroid disorders such as hyperthyroidism, thyrotoxicosis, subclinical hypothyroidism, Hashimoto's thyroiditis.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.2 Pharmacokinetic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.3 Preclinical safety data
Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.
6. Pharmaceutical particulars
6.1 List of excipients
Tablet core:
Lactose Monohydrate
Sodium Starch Glycollate
Calcium Hydrogen Phosphate Dihydrate (E341)
Talc
Magnesium Stearate
Tablet coating:
Titanium Dioxide (E171)
Talc
Kaolin Light
Sucrose
Acacia
Shellac
6.2 Incompatibilities
None.
6.3 Shelf life
36 months.
6.4 Special precautions for storage
None.
Store in the original package.
6.5 Nature and contents of container
White polypropylene containers with tamper-evident polyethylene moulded cap or integral polypropylene cap. Containing 50 or 100 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
No special requirements.
7. Marketing authorisation holder
Brome and Schimmer Limited
T/A Diomed Herbals
Tatmore Place
Gosmore
Hitchin
Herts SG4 7QR
UK
8. Marketing authorisation number
THR17418/0028
9. Date of first authorisation/renewal of the authorisation
10/04/2013
10. Date of revision of the text
19/11/2020